Clin2
NCT06366464Possibly a fitRecruiting

Study of a drug for sleepiness in Prader-Willi syndrome

Prader-Willi Syndrome

Treatments studied

Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism, Mental health clinical trials.

This trial tests a medication called pitolisant to see if it helps reduce excessive daytime sleepiness in people with Prader-Willi syndrome. You or your loved one may be able to join if they have a confirmed diagnosis and a caregiver who can regularly help with study tasks.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
134 people
Ages
6 years and older
Study type
Interventional

Who can take part

  • You must have a confirmed genetic diagnosis of Prader-Willi syndrome.
  • You must experience significant sleepiness during the day.
  • You need a parent or caregiver who is willing and able to assist with study assessments throughout the trial.
  • Sleep apnea, if present, must be well controlled.
  • You cannot have another sleep disorder causing your sleepiness, and you cannot be in another research study involving an experimental drug, device, or behavior treatment within the last 30 days or 5 half-lives.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07219485Enrolling by invitation· Phase 3
Pitolisant for Prader-Willi syndrome in ongoing study

This study tests an oral medication, pitolisant, in people with Prader-Willi syndrome who have already been in a pitolisant study. It aims to see if continuing treatment is safe and effective.

Morrisville, North Carolina
NCT05939453Recruiting
Bright light therapy for Prader-Willi sleepiness

This trial studies whether daily bright light therapy can reduce sleepiness in people with Prader-Willi syndrome. It may help by improving daytime alertness, but you must meet specific sleepiness, eye-safety, and mental health criteria to join.

Brooklyn, New York
NCT07348601Recruiting· Phase 2
Study of CSTI-500 for people with Prader-Willi syndrome

This trial tests an investigational drug called CSTI-500 for people with Prader-Willi syndrome who are in the hyperphagia (constant hunger) phase. It aims to see if the drug can improve behavior and reduce overeating. You and your caregiver will need to visit the clinic regularly and answer questions about symptoms.

Nashville, Tennessee
NCT04484051Not yet recruiting
Growth hormone study for adults with Prader-Willi syndrome

This study tests whether growth hormone treatment is safe and helpful for adults who have Prader-Willi syndrome. You might be considered if your diagnosis is confirmed and certain health risks—like diabetes and sleep breathing problems—are under control.

Rotterdam, South Holland
NCT07266324Not yet recruiting· Phase 2
BMB-101 for Prader-Willi Syndrome

This trial tests an experimental drug called BMB-101 to see if it can help control extreme hunger in adults with Prader-Willi Syndrome. It aims to improve safety and quality of life.

Sydney, New South Wales
NCT07500090Recruiting· Phase 3
Study of HBS-301 for idiopathic hypersomnia

This trial tests a new medication, HBS-301, in people with idiopathic hypersomnia (a condition causing excessive sleepiness without clear cause). It aims to see if the drug improves wakefulness and is safe.

Birmingham, Alabama

Hear when a new Prader-Willi Syndrome trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.